UBS/CALL/ROCHE GS/300.004/0.025/20.12.24 Stock

Warrant

UWROGU

CH0589946463

Market Closed - Swiss Exchange 11:15:00 2024-05-23 EDT
0.03 CHF -18.92% Intraday chart for UBS/CALL/ROCHE GS/300.004/0.025/20.12.24
Current month+3.45%
1 month-16.67%
Date Price Change
24-05-23 0.03 -18.92%
24-05-22 0.037 0.00%
24-05-21 0.037 +2.78%

Delayed Quote Swiss Exchange

Last update May 23, 2024 at 11:15 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
UWROGU
ISINCH0589946463
Date issued 2021-01-13
Strike 300 CHF
Maturity 2024-12-20 (211 Days)
Parity 40 : 1
Emission price 0.91 CHF
Emission volume N/A
Settlement physique
Currency CHF

Technical Indicators

Highest since issue 2.714 CHF
Lowest since issue 0.029 CHF
Delta0.07x
Omega 14.77
Premium29.76x
Gearing200.09x
Moneyness 0.7737
Difference Strike 67.9 CHF
Difference Strike %+22.63%
Spread 0.008 CHF
Spread %24.24%
Theoretical value 0.0290
Implied Volatility 21.27 %
Total Loss Probability 94.64 %
Intrinsic value 0.000000
Present value 0.0290
Break even 301.16 CHF
Theta-0x
Vega0.01x
Rho0x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
231.9 CHF
Average target price
279.4 CHF
Spread / Average Target
+20.48%
Consensus
  1. Stock Market
  2. Warrants
  3. UWROGU Warrant